135 related articles for article (PubMed ID: 2531841)
1. Factor C3f is a spasmogenic fragment released from C3b by factors I and H: the heptadeca-peptide C3f was synthesized and characterized.
Ganu VS; Müller-Eberhard HJ; Hugli TE
Mol Immunol; 1989 Oct; 26(10):939-48. PubMed ID: 2531841
[TBL] [Abstract][Full Text] [Related]
2. Physiologic inactivation of fluid phase C3b: isolation and structural analysis of C3c, C3d,g (alpha 2D), and C3g.
Davis AE; Harrison RA; Lachmann PJ
J Immunol; 1984 Apr; 132(4):1960-6. PubMed ID: 6607952
[TBL] [Abstract][Full Text] [Related]
3. Structure of C3f, a small peptide specifically released during inactivation of the third component of complement.
Harrison RA; Farries TC; Northrop FD; Lachmann PJ; Davis AE
Complement; 1988; 5(1):27-32. PubMed ID: 3338271
[TBL] [Abstract][Full Text] [Related]
4. The active site of human C4a anaphylatoxin.
Hugli TE; Kawahara MS; Unson CG; Molinar-Rode R; Erickson BW
Mol Immunol; 1983 Jun; 20(6):637-45. PubMed ID: 6603573
[TBL] [Abstract][Full Text] [Related]
5. Preparation of complement fragments C3b and C3a from purified rat complement component C3 by activated cobra venom factor.
Usami M; Ohno Y
J Pharmacol Toxicol Methods; 2005; 52(2):260-3. PubMed ID: 16125624
[TBL] [Abstract][Full Text] [Related]
6. Synthetic peptides with the biological activities and specificity of human C3a anaphylatoxin.
Hugli TE; Erickson BW
Proc Natl Acad Sci U S A; 1977 May; 74(5):1826-30. PubMed ID: 266705
[TBL] [Abstract][Full Text] [Related]
7. Functional consequences of the genetic polymorphism of the third component of complement.
Welch TR; Beischel L; Kleesattel A
J Pediatr; 1990 May; 116(5):S92-7. PubMed ID: 2139466
[TBL] [Abstract][Full Text] [Related]
8. Regulatory system of guinea-pig complement C3b: tests for compatibility of guinea-pig factors H and I with human factors.
Seya T; Okada M; Hazeki K; Nagasawa S
Mol Immunol; 1991; 28(4-5):375-82. PubMed ID: 1829503
[TBL] [Abstract][Full Text] [Related]
9. The active site of C3a anaphylatoxin.
Caporale LH; Tippett PS; Erickson BW; Hugli TE
J Biol Chem; 1980 Nov; 255(22):10758-63. PubMed ID: 6968751
[TBL] [Abstract][Full Text] [Related]
10. A revised mechanism for the activation of complement C3 to C3b: a molecular explanation of a disease-associated polymorphism.
Rodriguez E; Nan R; Li K; Gor J; Perkins SJ
J Biol Chem; 2015 Jan; 290(4):2334-50. PubMed ID: 25488663
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of factor I by diisopropylfluorophosphate. Evidence of conformational changes in factor I induced by C3b and additional studies on the specificity of factor I.
Ekdahl KN; Nilsson UR; Nilsson B
J Immunol; 1990 Jun; 144(11):4269-74. PubMed ID: 2140392
[TBL] [Abstract][Full Text] [Related]
12. Amino acid sequence of guinea pig C3a anaphylatoxin.
Gerard NP; Lively MO; Gerard C
Protein Seq Data Anal; 1988; 1(6):473-8. PubMed ID: 3064079
[TBL] [Abstract][Full Text] [Related]
13. Characterization of C3 in C3 glomerulopathy.
Sethi S; Vrana JA; Fervenza FC; Theis JD; Sethi A; Kurtin PJ; Zhang Y; Smith RJH
Nephrol Dial Transplant; 2017 Mar; 32(3):459-465. PubMed ID: 27507892
[TBL] [Abstract][Full Text] [Related]
14. Identification of classical anaphylatoxin as the des-Arg form of the C5a molecule: evidence of a modulator role for the oligosaccharide unit in human des-Arg74-C5a.
Gerard C; Hugli TE
Proc Natl Acad Sci U S A; 1981 Mar; 78(3):1833-7. PubMed ID: 6940191
[TBL] [Abstract][Full Text] [Related]
15. Investigation of mechanism-based inhibitors of complement targeting the activated thioester of human C3.
Sahu A; Pangburn MK
Biochem Pharmacol; 1996 Mar; 51(6):797-804. PubMed ID: 8602875
[TBL] [Abstract][Full Text] [Related]
16. A synthetic nonapeptide corresponding to the NH2-terminal sequence of C3d-K causes leukocytosis in rabbits.
Hoeprich PD; Dahinden CA; Lachmann PJ; Davis AE; Hugli TE
J Biol Chem; 1985 Mar; 260(5):2597-600. PubMed ID: 3871772
[TBL] [Abstract][Full Text] [Related]
17. Interaction of desialated guinea pig erythrocytes with the classical and alternative pathways of guinea pig complement in vivo and in vitro.
Brown EJ; Joiner KA; Frank MM
J Clin Invest; 1983 Jun; 71(6):1710-9. PubMed ID: 6863540
[TBL] [Abstract][Full Text] [Related]
18. A discontinuous factor H binding site in the third component of complement as delineated by synthetic peptides.
Lambris JD; Avila D; Becherer JD; Müller-Eberhard HJ
J Biol Chem; 1988 Aug; 263(24):12147-50. PubMed ID: 2969896
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the binding of C3S and C3F to complement receptors types 1, 2, and 3.
Bartók I; Walport MJ
J Immunol; 1995 May; 154(10):5367-75. PubMed ID: 7730637
[TBL] [Abstract][Full Text] [Related]
20. Paroxysmal nocturnal hemoglobinuria: deficiency in factor H-like functions of the abnormal erythrocytes.
Pangburn MK; Schreiber RD; Trombold JS; Müller-Eberhard HJ
J Exp Med; 1983 Jun; 157(6):1971-80. PubMed ID: 6222136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
